Takeda to acquire Adaptate Biotherapeutics
Acquisition adds Adaptate’s novel antibody-based ?? T-cell engager platform to Takeda’s Immuno-oncology portfolio built around the Innate Immune System
Acquisition adds Adaptate’s novel antibody-based ?? T-cell engager platform to Takeda’s Immuno-oncology portfolio built around the Innate Immune System
Cobas infinity edge is designed as an open platform, allowing healthcare professionals to easily access and adopt third-party innovators’ new digital tools and medically-relevant applications via the Roche digital marketplace
The company’s platform technology works like a compression algorithm for molecular testing and has applications in healthcare, pharmaceuticals, agriculture, animal husbandry, food safety, synthetic biology, and molecular biology research
The HALO AP platform was developed by Indica Labs to address the specific needs of anatomic pathology labs by supporting a wide range of tissue-based workflows, including primary diagnosis, secondary consults, tumour boards, clinical trials, synoptic reporting, quantitative analytics, and AI
Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition
The virtual world makes it possible to visualize, test, understand and predict what cannot be seen, before a patient is treated
This next-generation CAR T construct was designed to improve the tolerability profile of conventional CD19 CAR Ts and developed in the laboratory of James N. Kochenderfer, M.D., at the National Cancer Institute, part of the NIH, the same laboratory that discovered axicabtagene ciloleucel
A toll-free helpline to be set up to help doctors and patients
G42 Healthcare and AstraZeneca will work closely together to explore real-world evidence and conduct clinical trials through IROS – the first-of-its-kind Contract Research Organization (CRO) in the UAE
Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2
Subscribe To Our Newsletter & Stay Updated